Pseudosystemic sclerosis as a complication of recombinant human interleukin 2 (aldesleukin) therapy.
Marie
I
I
Joly
P
P
Courville
P
P
Levesqsue
H
H
D000970:Antineoplastic Agents / Q000009:adverse effects*; D002292:Carcinoma, Renal Cell / Q000188:drug therapy; D005260:Female; D006801:Humans; D007376:Interleukin-2 / Q000009:adverse effects / Q000031:analogs & derivatives*; D008875:Middle Aged; D011994:Recombinant Proteins / Q000009:adverse effects; D012595:Scleroderma, Systemic / Q000139:chemically induced*
D000970:Antineoplastic Agents; D007376:Interleukin-2; D011994:Recombinant Proteins; C082598:aldesleukin